LONDON (ShareCast) - (Sharecast News) - Crism Therapeutics used its annual general meeting on Tuesday to highlight progress on its ChemoSeed drug delivery platform as it advances towards key clinical milestones.
Non-executive chair Dr Nermeen Varawalla told shareholders the company had submitted its clinical trial authorisation application to the UK's Medicines and Healthcare products Regulatory Agency in June for a phase two study of irinotecan ChemoSeed in patients with resectable glioblastoma.

Production of a clinical batch under Good Manufacturing Practice had also begun with ProMed Pharma, supported by £874,021 raised in a June funding round.

Dr Varawalla said the potential for ChemoSeed extended beyond glioblastoma, noting a grant from Innovate UK in March to support pre-clinical development for prostate cancer.

"Going forward we are focused on gaining trial approval from the MHRA in glioblastoma and progressing towards dosing our first patients in early 2026," she added.

"Additionally, we will continue to seek further validation for our novel delivery method and are confident that ChemoSeed has the potential to transform treatment for patients with solid-tumour cancers."

The company also said it had established an Enterprise Management Incentives Option Plan to attract and retain talent as it pursues its development goals.

At 0954 BST, shares in Crism Therapeutics Corporation were down 4.76% at 10p.

Reporting by Josh White for Sharecast.com.

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE